September 5, 2017 / 5:05 AM / 4 months ago

BRIEF-Novimmune ‍receives rare pediatric disease designation from FDA for its lead drug emapalumab​

Sept 5 (Reuters) - Novimmune SA (IPO-NOVI.S):

    * ‍RECEIVES RARE PEDIATRIC DISEASE DESIGNATION FROM FDA FOR ITS LEAD DRUG EMAPALUMAB​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

    0 : 0
    • narrow-browser-and-phone
    • medium-browser-and-portrait-tablet
    • landscape-tablet
    • medium-wide-browser
    • wide-browser-and-larger
    • medium-browser-and-landscape-tablet
    • medium-wide-browser-and-larger
    • above-phone
    • portrait-tablet-and-above
    • above-portrait-tablet
    • landscape-tablet-and-above
    • landscape-tablet-and-medium-wide-browser
    • portrait-tablet-and-below
    • landscape-tablet-and-below